共 58 条
[1]
Furqan M(2013)Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application Biomark Res 1 5-36
[2]
Mukhi N(2016)Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases Nat Rev Rheumatol 12 25-2613
[3]
Lee B(2013)JAK/STAT signaling in hematological malignancies Oncogene 32 2601-898
[4]
Liu D(2017)Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis Oncoimmunology 6 e1345402-796
[5]
Schwartz DM(2019)Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia Cancer Chemother Pharmacol 84 891-321
[6]
Bonelli M(2011)Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis J Clin Oncol 29 789-421
[7]
Gadina M(2015)A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis Blood Cancer J 5 e335-17
[8]
O'Shea JJ(2015)Effect of food on the bioavailability and tolerability of the JAK2-selective inhibitor fedratinib (SAR302503): results from two phase I studies in healthy volunteers Clin Pharmacol Drug Dev 4 315-766
[9]
Vainchenker W(2014)A randomized, placebo-controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteers J Clin Pharmacol 54 415-471
[10]
Constantinescu SN(1999)Cytochrome P-450 3A4: regulation and role in drug metabolism Annu Rev Pharmacol Toxicol 39 1-359